Trial site

Encore Medical Research

Hollywood, Florida 33024, United StatesNot linked to an institution yet

14running trials
10closed trials

The trials here

What the 24 trials at this site are about, from their registry records.

Conditions: Type 2 diabetes9 trials
Obesity7 trials
Atopic dermatitis (eczema)3 trials
Irritable bowel syndrome2 trials
Psoriasis2 trials
Type 1 diabetes2 trials
Chronic kidney disease1 trial
Coronary artery disease1 trial
Depression1 trial
Familial hypercholesterolaemia1 trial
Fatty liver disease (MASLD/MASH)1 trial
Lichen planus1 trial
and 2 more
Phase: Phase 315 trials
Phase 26 trials
Phase 42 trials
Phase 11 trial
Status: Completed9 trials
Recruiting8 trials
Active, not recruiting6 trials
Terminated1 trial
Lead sponsor: Eli Lilly and Company18 trials
Novartis Pharmaceuticals3 trials
Boehringer Ingelheim2 trials
Concerto Biosciences1 trial

Running trials

Recruiting
A Study to Assess the Efficacy and Safety of GIA632 Across a Range of Doses in Participants With Moderate to Severe Cutaneous Lichen Planus
NCT07775924· Phase 2· Novartis Pharmaceuticals· Source
Contact: Yeniska Hall
Recruiting
A Study to Test Whether Survodutide Helps People With Type 2 Diabetes Control Their Blood Sugar
NCT07754461· Phase 3· Boehringer Ingelheim· Source
Contact: Boehringer Ingelheim
Recruiting
A Study of Brenipatide (LY3537031) in Participants With Irritable Bowel Syndrome-Diarrhea (IBS-D)
NCT07545759· Phase 2· Eli Lilly and Company· Source
Contact: Rodolfo Perez (principal investigator)
Recruiting
A Study of Brenipatide (LY3537031) in Participants With Irritable Bowel Syndrome-Constipation (IBS-C)
NCT07545772· Phase 2· Eli Lilly and Company· Source
Contact: Rodolfo Perez (principal investigator)
Recruiting
A Phase IIb Dose-ranging Study to Assess the Efficacy and Safety of GIA632 in Participants With Non-segmental Vitiligo
NCT07431177· Phase 2· Novartis Pharmaceuticals· Source
Contact: Yeniska Hall
Recruiting
A Study of Brenipatide in Adult Participants With Major Depressive Disorder
NCT07412756· Phase 3· Eli Lilly and Company· Source
Contact: Juan Oms (principal investigator)
Recruiting
A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
NCT07165028· Phase 3· Eli Lilly and Company· Source
Contact: Rodolfo Perez (principal investigator)
Active, not recruiting
A Study of LY3938577 in Participants With Type 2 Diabetes Previously Treated With Basal Insulin
NCT07215312· Phase 2· Eli Lilly and Company· Source
Active, not recruiting
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 Diabetes
NCT06972472· Phase 3· Eli Lilly and Company· Source
Active, not recruiting
A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes
NCT06993792· Phase 3· Eli Lilly and Company· Source
Active, not recruiting
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related Comorbidity
NCT06972459· Phase 3· Eli Lilly and Company· Source
Recruiting
A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO)
NCT06857942· Phase 4· Eli Lilly and Company· Source
Contact: Jerome Obed (principal investigator)
Active, not recruiting
A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have Obesity
NCT06662383· Phase 3· Eli Lilly and Company· Source
Active, not recruiting
A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.
NCT05739383· Phase 3· Novartis Pharmaceuticals· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

Irritable bowel syndrome2 recruiting
Depression1 recruiting
Fatty liver disease (MASLD/MASH)1 recruiting
Lichen planus1 recruiting
Obesity1 recruiting
Psoriasis1 recruiting
Type 2 diabetes1 recruiting
Vitiligo1 recruiting

Closed trials

Completed
A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Chronic Kidney Disease
NCT06926660· Phase 2· Boehringer Ingelheim· Source
Completed
A Study to See How Well Lebrikizumab Works in Adults and Adolescents With Moderate Atopic Dermatitis (Eczema) and High Itch Burden
NCT07006792· Phase 4· Eli Lilly and Company· Source
Completed
A Study to Investigate the Efficacy and Safety of Lebrikizumab in Participants With Moderate-to-Severe Atopic Hand and Foot Dermatitis
NCT06921759· Phase 3· Eli Lilly and Company· Source
Completed
Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight
NCT06588283· Phase 3· Eli Lilly and Company· Source
Terminated
Topical ENS-002 for Atopic Dermatitis in Adults
NCT06469385· Phase 1· Concerto Biosciences· Source
Completed
A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes and Inadequate Glycemic Control With Insulin Glargine, With or Without Metformin and/or SGLT-2 Inhibitor
NCT06109311· Phase 3· Eli Lilly and Company· Source
Completed
A Study of Orforglipron in Adult Participants With Obesity or Overweight and Type 2 Diabetes
NCT05872620· Phase 3· Eli Lilly and Company· Source
Completed
A Study of Insulin Efsitora Alfa (LY3209590) Compared With Insulin Degludec in Participants With Type 2 Diabetes Currently Treated With Basal Insulin
NCT05275400· Phase 3· Eli Lilly and Company· Source
Completed
Long-term Safety and Efficacy Study of Lebrikizumab (LY3650150) in Participants With Moderate-to-Severe Atopic Dermatitis (ADjoin)
NCT04392154· Phase 3· Eli Lilly and Company· Source
Completed
A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes
NCT04255433· Phase 3· Eli Lilly and Company· Source

Site data: ClinicalTrials.govUpdated 15 Nov 2026

Report an error